Clinical MR Spectroscopy of Brain Metastases at 1,5T and 3T.
Completed
- Conditions
- Neoplasm Metastases
- Registration Number
- NCT00184353
- Lead Sponsor
- Norwegian University of Science and Technology
- Brief Summary
Increasing magnetic field is known to give improvements in signal-to-noise-ratio (SNR) and spectral resolution. To investigate this, spectra from different subjects were examined using two clinical MR instruments operating at 1.5T and 3T respectively.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 19
Inclusion Criteria
- brain metastases
Exclusion Criteria
- children
- pregnancy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie brain metastases progression in neoplasm patients using proton MR spectroscopy?
How does 3T MRI compare to 1.5T in detecting metabolic biomarkers for brain metastases prognosis?
Are there specific biomarkers identified via MR spectroscopy that predict treatment response in brain metastases?
What adverse events are associated with high-field MR spectroscopy in brain metastases studies?
How do 1.5T and 3T MR spectroscopy findings influence current therapeutic strategies for brain metastases?
Trial Locations
- Locations (1)
Norwegian University of Science and Technology
🇳🇴Trondheim, Norway
Norwegian University of Science and Technology🇳🇴Trondheim, Norway